Wortmannin enhances cisplatin-induced apoptosis in human ovarian cancer cells in vitro

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 17, 2014, Pages 2428-2434

  Zhao, J X ^a   Liu, H ^b   Lv, J ^a   Yang, X J ^a  

^a QINGDAO UNIVERSITY   (China)

^b PEOPLE S HOSPITAL OF RIZHAO   (China)

Author keywords

Atherosclerosis (AS); Homocysteine (Hcy); Lutein; Oxidative stress

Indexed keywords

CISPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; WORTMANNIN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR INVASION; UPREGULATION; DOWN REGULATION; DRUG EFFECTS; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DOWN-REGULATION; DRUG SYNERGISM; FEMALE; HUMANS; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84919938502     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. KHALIL I, BREWER MA, NEYARAPALLY T, RUNOWICZ CD. The potential of biologic network models in understanding the etiopathogenesis of ovarian cancer. Gynecol Oncol 2010;116:282-285.
2. KÖBEL M, KALLOGER SE, BOYD N, MCKINNEY S, MEHL E, PALMER C, LEUNG S, BOWEN NJ, IONESCU DN, RAJPUT A, PRENTICE LM, MILLER D, SANTOS J, SWENERTON K, GILKS CB, HUNTSMAN D. Ovarian carcinoma subtypes are different diseases: Implications for biomarker studies. PLoS Med 2008;5:1749-1760.
3. CANADIAN CANCER SOCIETY. Canadian Cancer Statistics. Statistics Canada/Public Health Agency of Canada, 2011.
4. HOLSCHNEIDER C, BEREK J. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 2000;19:3-10.
5. MOORE R, MACLAUGHLIN S. Current clinical use of biomarkers for epithelial ovarian cancer. Curr Opin Oncol 2010;22:492-497.
6. KULASINGAM V, PAVLOU M P, DIAMANDIS EP. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev 2010;10:371-378.
7. VISINTIN I, FENG Z, LONGTON G, WARD DC, ALVERO AB, LAI Y, TENTHOREY J, LEISER A, FLORES-SAAIB R, YU H, AZORI M, RUTHERFORD T, SCHWARTZ PE, MOR G. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14:1065-1072.
8. DRESSMAN HK, BERCHUCK A, CHAN G, ZHAI J, BILD A, SAYER R, CRAGUN J, CLARKE J, WHITAKER RS, LI L, GRAY J, MARKS J, GINSBURG GS, POTTI A, WEST M, NEVINS JR, LANCASTER JM. An integrated genomic-based approach to individualized treatment of patients with advanced stage ovarian cancer. J Clin Oncol 2007;25:517-525.
9. YEN MS, JUANG CM, LAI CR, CHAO GC, NG HT, YUAN CC. Intraperitoneal cisplatin-based chemotherapy vs.intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int J Gynaecol Obstet 2001;72:55-60.
10. HOGBERG T. Chemotherapy: current drugs still have potential in advanced ovarian cancer. Nat Rev Clin Oncol 2010;7:191-193.
11. MARSH S. Pharmacogenomics of Taxane/Platinum therapy in ovarian cancer. Int J Gynecol Cancer 2009;2:30-34.
12. GALLUZZI L, SENOVILLA L, VITALE I, MICHELS J, MARTINS I, KEPP O, CASTEDO M, KROEMER G. Molecular mechanisms of cisplatin resistance. Oncogene 2012;31:1869-1883.
13. KONSTANTINOPOLOUS PA, SPENTZOS D, CANNISTRA S. Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol 2008;5:577-587.
14. LI J, WOOD WH, BECKER KG, WEERARATNA AT, MORIN PJ. Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells. Oncogene 2007;26:2860-2872.
15. CHENG TC, MANOREK G, SAMIMI G, LIN X, BERRY CC, HOWELL SB. Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 2006;58:384-395.
16. AHMAD S. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem Biodivers 2010;7:543-566.
17. BURGER H, LOOS WJ, EECHOUTE K, VERWEIJ J, MATHIJSSEN RH, WIEMER EA. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Update 2011;14:22-34.
18. DATTA SR, BRUNET A, GREENBERG ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-2927.
19. KATSO R, OKKENHAUG K, AHMADI K, WHITE S, TIMMS J, WATERFIELD MD. Cellular function of phosphoinosi-tide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001;17:615-675.
20. LUO J, MANNING BD, CANTLEY LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257-262.
21. WEST KA, CASTILLO SS, DENNIS PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 2002;5:234-248.
22. NICHOLSON KM, ANDERSON NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002;14:381-395.
23. VIVANCO I, SAWYERS CL. The phosphatidylinositol 3-kinase Akt pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
24. SUN M, WANG G, PACIGA JE, FELDMAN RI, YUAN ZQ, MA XL, SHELLEY SA, JOVE R, TSICHLIS PN, NICOSIA S V, CHENG JQ. Akt1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic trans-formation in NIH3T3 cells. Am J Pathol 2001;159:431-437.
25. POWIS G, BONJOUKLIAN R, BERGGREN MM, GALLEGOS A, ABRAHAM R, ASHENDEL C, ZALKOW L, MATTER W F, DODGE J, GRINDEY G. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res 1994;54:2419-2423.
26. YAO R, COOPER GM. Requirement for phosphatidyli-nositol 3-kinase in the prevention of apoptosis by nerve growth factor. Nature (Lond.) 1995;267:2003-2006.
27. WANG J, CHEN Y, ZHANG W, ZHENG G, MENG S, CHE H, KE T, YANG J, CHEN J, LUO W. Akt activation protects liver cells from apoptosis in rats during acute cold exposure. Int J Biol Sci 2013;9:509-517.
28. YUN J, LV YG, YAO Q, WANG L, LI Y P, YI J. Wortman-nin inhibits proliferation and induces apoptosis of MCF-7 breast cancer cells. Eur J Gynaecol Oncol 2012;33:367-369.
29. KIM W, SEONG J, AN JH, OH HJ. Enhancement of tumor radioresponse by wortmannin in C3H/HeJ hepatocarcinoma. J Radiat Res 2007;48:187-195.
30. SOLAR P, SYTKOWSKI AJ. Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780. Cancer Lett 2011;309:11-18.
31. CLARK AS, WEST K, STREICHER S, DENNIS PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2012;1:707-717.
32. PAGE C, LIN HJ, JIN Y, CASTLE V P, NUNEZ G, HUANG M, LIN J. Overexpression of Akt/Akt can modulate chemotherapy-induced apoptosis. Anticancer Res 2010;20:407-416.
33. OHTA T, OHMICHI M, HAYASAKA T, MABUCHI S, SAITOH M, KAWAGOE J, TAKAHASHI K, IGARASHI H, DU B, DOSHIDA M, MIREI IG, MOTOYAMA T, TASAKA K, KURACHI H. Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. Endocrinology 2006;147:1761-1769.
34. LIU AX, TESTA JR, HAMILTON TC, JOVE R, NICOSIA S V, CHENG JQ. AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res 1998;58:2973-2977.
35. HAYAKAWA J, OHMICHI M, KURACHI H, KANDA Y, HISAMOTO K, NISHIO Y, ADACHI K, TASAKA K, KANZAKI T, MURATA Y. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 2000;60:5988-5994.
36. SCHULTZ RM, MERRIMAN RL, ANDIS SL, BONJOUKLIAN R, GRINDEY GB, RUTHERFORD PG, GALLEGOS A, MASSEY K, POWIS G. In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res 1995;15:1135-1139.
37. QIAO M, SHENG S, PARDEE AB. Metastasis and AKT activation. Cell Cycle 2008;7:2991-2996.